Imagion Biosystems Limited (ASX:IBX)

Market Cap	12.26M +204.6%
Revenue (ttm)	1.06M -82.2%
Net Income	-2.20M
EPS	-0.02
Shares Out	490.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	744,968
Average Volume	2,191,916
Open	0.0250
Previous Close	0.0250
Day's Range	0.0250 - 0.0250
52-Week Range	0.0110 - 0.0550
Beta	-0.16
RSI	49.38
Earnings Date	Feb 26, 2026

About Imagion Biosystems

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IBX

Financial Performance

In 2024, Imagion Biosystems's revenue was 2.67 million, a decrease of -46.38% compared to the previous year's 4.97 million. Losses were -2.07 million, -83.43% less than in 2023.